1,2-Dihydro-2,2-dimethylquinoxaline | 149179-69-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 1,2-Dihydro-2,2-dimethylquinoxaline
• 英文别名: 2,2-dimethyl-1H-quinoxaline
• CAS: 149179-69-1
• 化学式: C₁₀H₁₂N₂
• 分子量: 160.219
• InChiKey: VIWPSECTMUVDCC-UHFFFAOYSA-N

物化性质

• 熔点：
  103-104 °C
• 沸点：
  288.5±33.0 °C(Predicted)
• 密度：
  1.07±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  24.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1-叠氮基-2-硝基苯 在 palladium on activated charcoal 水 、 氢气 作用下， 以 乙醇 、 二氯甲烷 、 甲苯 、 苯 为溶剂， 25.0 ℃ 、101.33 kPa 条件下， 反应 25.0h， 生成 1,2-Dihydro-2,2-dimethylquinoxaline
  参考文献：
  名称：

  Battistini, Maurizio; Erba, Emanuela; Pocar, Donato, Journal of the Chemical Society. Perkin transactions I, 1993, # 3, p. 339 - 342

  摘要：

  DOI：

文献信息

• A new facile, efficient synthesis and structure peculiarity of quinoxaline derivatives with two benzimidazole fragments
  作者：Vakhid A. Mamedov、Nataliya A. Zhukova、Victor V. Syakaev、Aidar T. Gubaidullin、Tat'yana N. Beschastnova、Dil'bar I. Adgamova、Aida I. Samigullina、Shamil K. Latypov

  DOI：10.1016/j.tet.2012.10.045

  日期：2013.1

  A highly efficient and versatile method for the synthesis of quinoxaline derivatives with two benzimidazole fragments have been developed on the basis of the ring contraction of 3-(benzimidazo-2-yl)quinoxalin-2(1H)-one with 1,2-diaminobenzene and its various types of substituted and condensed derivatives. Owing to the inter- and intramolecular processes, involving self association, proton exchange

  基于3-（苯并咪唑-2-基）喹喔啉-2（1 H）-与1,2-的环收缩，已开发出一种高效且通用的具有两个苯并咪唑片段的喹喔啉衍生物的合成方法。二氨基苯及其各种类型的取代和稠合衍生物。由于分子间和分子内过程，涉及桥联和相邻碳原子的大多数双-苯并咪唑基喹喔啉信号的几种形式之间的自缔合，质子交换，构象和/或互变异构交换，且NMR光谱中的苯并咪唑片段变宽。苯并咪唑片段与分子的喹喔啉核心之间的共轭作用比喹喔啉衍生物（10c）与其噻二唑[ f ]-（17）和吡咯并[ a ]-（19）环化了衍生物，导致整个分子的平面度更大。
• BISHETEROCYCLIC CARBONYL SUBSTITUTED DIHYDROPYRAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF
  申请人：Genfleet Therapeutics (Shanghai) Inc.

  公开号：EP3967682A1

  公开（公告）日：2022-03-16

  Provided are a substituted dihydropyrazole compound as shown in formula I, which compound has a selective inhibitory effect on RIPK1, and a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof, wherein the definition of each group in the formula is detailed in the description. In addition, also disclosed are a pharmaceutical composition containing the compound, and the use thereof in the preparation of a drug for treating RIPK1-related diseases or conditions.

  提供的是如公式I所示的一种替代二氢吡唑酮化合物，该化合物对RIPK1具有选择性抑制作用，以及其药用盐、立体异构体、溶剂合物或前药，其中公式中每个基团的定义在描述中有详细说明。此外，还披露了含有该化合物的药物组合物，以及在制备治疗RIPK1相关疾病或症状的药物中的使用。
• INDOLE DERIVATIVE-CONTAINING INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
  申请人：Shanghai Hansoh Biomedical Co., Ltd.

  公开号：EP3974423A1

  公开（公告）日：2022-03-30

  The present invention relates to an indole derivative-containing inhibitor, a preparation method therefor and an application thereof, and in particular, to a compound as represented by general formula (Ia), a preparation method therefor, a pharmaceutical composition comprising the compound, and the use thereof in treating related diseases such as cancer, inflammation, chronic liver disease, diabetes, cardiovascular disease, and AIDS as a kinase inhibitor, especially as a receptor tyrosine kinase inhibitor (TKI), more specifically, as an EGFR or HER2 inhibitor. The compound exhibits good inhibitory activity in EGFR and HER2 20 exon mutations.

  本发明涉及一种含有吲哚衍生物的抑制剂，其制备方法和应用，特别是一种由一般式（Ia）所代表的化合物，其制备方法，包括该化合物的制药组合物以及其作为激酶抑制剂的用途，特别是作为受体酪氨酸激酶抑制剂（TKI），更具体地作为EGFR或HER2抑制剂，用于治疗癌症、炎症、慢性肝病、糖尿病、心血管疾病和艾滋病等相关疾病。该化合物在EGFR和HER2 20外显子突变中表现出良好的抑制活性。
• SUBSTITUTED FUSED BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN MEDICINES
  申请人：Jiangsu Hengrui Medicine Co., Ltd.

  公开号：EP3978498A1

  公开（公告）日：2022-04-06

  The present application relates to a substituted fused bicyclic derivative, a preparation method therefor, and an application thereof in medicines. Specifically, the present application relates to a novel substituted fused bicyclic derivative as represented by formula (I), a preparation method therefor, a pharmaceutical composition containing the derivative, an application thereof as a therapeutic agent, in particular, as an ERK inhibitor, and an application thereof in preparation of medicines for treatment and/or prevention of cancer, inflammation, or other proliferative diseases, wherein the definitions of the substituents in formula (I) are the same as those in the description.

  本申请涉及一种取代融合双环衍生物、其制备方法及在药物中的应用。具体而言，本申请涉及一种新型取代融合双环衍生物，其由公式（I）表示，其制备方法，含有该衍生物的药物组合物，其作为治疗剂的应用，特别是作为ERK抑制剂的应用，以及其在制备治疗和/或预防癌症、炎症或其他增生性疾病的药物中的应用，其中公式（I）中取代基的定义与说明中的相同。
• Cycloalkyl inhibitors of potassium channel function
  申请人：Bristol-Myers Squibb Company

  公开号：EP2253328A1

  公开（公告）日：2010-11-24

  Novel cycloalkyl compounds useful as inhibitors of potassium channel function (especially inhibitors of the Kvl subfamily of voltage gated K+ channels, especially inhibitors Kv1.5 which has been linked to the ultra-rapidly activating delayed rectifier K+ current IKur), methods of using such compounds in the prevention and treatment of arrhythmia and IKur-associated conditions, and pharmaceutical compositions containing such compounds.

  可用作钾通道功能抑制剂的新型环烷基化合物（特别是电压门控 K+ 通道 Kvl 亚家族的抑制剂，尤其是与超快速活化延迟整流 K+ 电流 IKur 有关的 Kv1.5 抑制剂）、使用此类化合物预防和治疗心律失常及 IKur 相关疾病的方法，以及含有此类化合物的药物组合物。